Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Volunteers During a Blood Draw

To determine if a manual blood loss can be detected using the non-invasive blood monitor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Loss Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

DaVita Clinical Research

Lakewood, Colorado, 80228, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy volunteer
between 18 to 50 years of age
weight between 157 to 220 lbs

Exclusion criteria

unstable or untreated cardia disease
alcohol consumption in 24 hours prior to screening
tobacco use in 4 hours prior to screening
pregnancy
infection
Hemoglobin < 12.5 g/dL at time of procedure

Treatment and study plan

CM1500

Device

blood volume monitor

Primary outcomes

Detect change in blood volume by non-invasive monitoring during whole blood draw

Time frame: 4 months

Sponsors and collaborators

Lead sponsor

Zynex Monitoring Solutions

Industry

Registry information

Official study title

Clinical Evaluation of the Zynex Blood Volume Monitor (CM1500) in Healthy Adult Volunteers During a Blood Draw

Important dates

Study start: 2013
Primary completion: 2013
Study completion: 2013
First posted: Apr 18, 2013
Registry last updated: Jul 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed